–
Статьи в журналах
-
- 2025 Аnalyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (ARCC) treated with lenvatinib + pembrolizumab (l+P) in the phase 3 CLEAR trial
- Grünwald V., Keizman D., Bedke J., Staehler M.D., Matveev V.B., George S., Hutson T.E., Vaishampayan U.N., Merchan Ja R., Eto M., Rha S.Y., Waddell T., Sabbatini R., Barthelemy Ph, Burgents J.E., Ren M., Ia Brown, Saal H., Choueiri T.K., Motzer R.J.
- в журнале Journal of Clinical Oncology, издательство American Society of Clinical Oncology (United States), том 43, № 5, с. 531-10